Hypoxia‐inducible factor‐1 (HIF‐1) inhibitors from the last decade (2007 to 2016): A “structure–activity relationship” perspective

D Bhattarai, X Xu, K Lee - Medicinal research reviews, 2018 - Wiley Online Library
Tumor hypoxia is a common feature in most solid tumors and is associated with
overexpression of the hypoxia response pathway. Overexpression of the hypoxia‐inducible …

Targeting transcription factors by small compounds—Current strategies and future implications

J Hagenbuchner, MJ Ausserlechner - Biochemical pharmacology, 2016 - Elsevier
Transcription factors are central regulators of gene expression and critically steer
development, differentiation and death. Except for ligand-activated nuclear receptors, direct …

Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014

Y Xiao, Y Liu - Current Drug Targets, 2020 - ingentaconnect.com
HSP90 is a member of the family of heat shock proteins responsible for folding proteins into
mature conformations and thus maintaining their biological function in cells. Since it is …

Novel hypoxia-inducible factor 1α (HIF-1α) inhibitors for angiogenesis-related ocular diseases: discovery of a novel scaffold via ring-truncation strategy

H An, S Lee, JM Lee, DH Jo, J Kim… - Journal of Medicinal …, 2018 - ACS Publications
Ocular diseases featuring pathologic neovascularization are the leading cause of blindness,
and anti-VEGF agents have been conventionally used to treat these diseases. Recently …

Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

SY Hyun, HT Le, CT Nguyen, YS Yong, HJ Boo… - Scientific reports, 2018 - nature.com
Despite the development of advanced therapeutic regimens such as molecular targeted
therapy and immunotherapy, the 5-year survival of patients with lung cancer is still less than …

Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential

RS Varughese, WST Lam, AAH Marican… - Cancer, 2019 - Wiley Online Library
Deguelin is a rotenoid compound that exists in abundant quantities in the bark, roots, and
leaves of the Leguminosae family of plants. An analysis of evidence from both in vitro and in …

Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer

CT Nguyen, MT La, J Ann, G Nam, HJ Park… - Bioorganic & Medicinal …, 2021 - Elsevier
A series of O-substituted analogs of the C-ring-truncated scaffold of deguelin designed as
heat shock protein 90 (HSP90) C-terminal inhibitors were investigated as novel antitumor …

Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies

WF Zuo, Q Pang, X Zhu, QQ Yang, Q Zhao… - Journal of Hematology & …, 2024 - Springer
Heat shock proteins are essential molecular chaperones that play crucial roles in stabilizing
protein structures, facilitating the repair or degradation of damaged proteins, and …

Discovery of novel aryl carboxamide derivatives as hypoxia-inducible factor 1α signaling inhibitors with potent activities of anticancer metastasis

M Liu, Y Liang, Z Zhu, J Wang, X Cheng… - Journal of Medicinal …, 2019 - ACS Publications
In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer
metastasis treatment, 68 new aryl carboxamide compounds were synthesized and …

Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90)

CT Nguyen, J Ann, R Sahu, WS Byun, S Lee… - Bioorganic & Medicinal …, 2020 - Elsevier
A series of O-substituted analogues of the B, C-ring truncated scaffold of deguelin were
designed as C-terminal inhibitors of heat shock protein 90 (HSP90) and investigated as …